The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma
Open accessAbstract
Introduction: Dupilumab, a fully human anti-IL-4Rα monoclonal antibody, inhibits signaling of both interleukin (IL)-4 and IL-13, which are key drivers of type 2-mediated inflammation. Dupilumab is approved in the EU, USA, and other countries for the treatment of adults with inadequately controlled moderate-to-severe atopic dermatitis. Following positive phase 2 results in asthma, the phase 3 Liberty Asthma QUEST trial was initiated to provide further evidence for dupilumab efficacy and safety in patients with uncontrolled, moderate-to-severe asthma. Methods: Liberty Asthma QUEST is a phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (NCT02414854) in patients with persistent asthma who are receiving continuous treatment with inhaled corticosteroids (ICS) plus one or two other asthma controller medicines. A total of 1902 patients (aged ≥ 12 years) were randomized in a 2:2:1:1 ratio to receive 52 weeks of add-on therapy with subcutaneously administered dupilumab 200 or 300 mg every 2 weeks or matched placebo. The study consisted of a 4 ± 1-week screening period, 52-week randomized treatment period, and 12-week post-treatment follow-up period. All patients continued to receive their prescribed ICS plus up to two additional controller medications. The primary efficacy endpoints were annualized rate of severe exacerbation events during the 52-week treatment period and absolute change from baseline in pre-bronchodilator FEV 1 at week 12. Conclusion: Uncontrolled asthma patients with persistent symptoms represent a population of significant unmet need, for whom new treatments are required. Patients with severe asthma are at high risk of asthma exacerbations, and face an accelerated decline in lung function and impaired quality of life. QUEST examines the efficacy of dupilumab in this at-risk patient population; it is the largest placebo-controlled study in uncontrolled, moderate-to-severe asthma with a biologic agent to date, and the only phase 3 study of a biologic therapy of asthma that enrolled patients irrespective of baseline type 2 inflammatory biomarker levels. Funding: Sanofi and Regeneron Pharmaceuticals, Inc. Clinical Trials.gov Identifier: NCT02414854.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cluster analysis and clinical asthma phenotypes
Haldar, P., Pavord, I. D., Shaw, D. E., Berry, M. A., Thomas, M., Brightling, C. E., Wardlaw, A. J., & Green, R. H. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1754oc · Cited by 1,987
Self-citationWenzel, S., Castro, M., Corren, J., Maspero, J., Wang, L., Zhang, B., Pirozzi, G., Sutherland, E. R., Evans, R. R., Joish, V. N., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30307-5 · Cited by 985
Self-citationTargeting key proximal drivers of type 2 inflammation in disease
Gandhi, N. A., Bennett, B. L., Graham, N. M. H., Pirozzi, G., Stahl, N., & Yancopoulos, G. D. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd4624 · Cited by 766
Self-citation
Cited by
Diver, S., Khalfaoui, L., Emson, C., Wenzel, S. E., Menzies-Gow, A., Wechsler, M. E., Johnston, J., Molfino, N., Parnes, J. R., Megally, A., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00226-5 · Cited by 328
Self-citationDupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
Hamilton, J. D., Harel, S., Swanson, B. N., Brian, W., Chen, Z., Rice, M. S., Amin, N., Ardeleanu, M., Radin, A., Shumel, B., et al. (2021) · Clinical & Experimental Allergy · doi:10.1111/cea.13954 · Cited by 192
Self-citation
Metadata
- Authors
- Busse, W. W., Maspero, J. F., Rabe, K. F., Papi, A., Wenzel, S. E., Ford, L. B., Pavord, I. D., Zhang, B., Staudinger, H., Pirozzi, G., Amin, N., Akinlade, B., Eckert, L., Chao, J., Graham, N. M. H., & Teper, A.
- Venue
- Advances in Therapy
- Published
- 2018-05
- Volume
- 35
- Issue
- 5
- Pages
- 737-748
- ISSN
- 0741-238X (ISSN-L)
- 1865-8652
- OpenAlex
- W2801759342
- Cited by
- 189
- References
- 3
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. https://app.cochat.ai/papers/10.1007/s12325-018-0702-4
- The paper
- Busse, W. W., Maspero, J. F., Rabe, K. F., Papi, A., Wenzel, S. E., Ford, L. B., Pavord, I. D., Zhang, B., Staudinger, H., Pirozzi, G., Amin, N., Akinlade, B., Eckert, L., Chao, J., Graham, N. M. H., & Teper, A. (2018). Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. Advances in Therapy. https://doi.org/10.1007/s12325-018-0702-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.